The stock of Oxford-AstraZeneca doses is running out fast but the government, despite frantic efforts to keep the inoculation campaign on track, is yet to secure a contract for bulk supply of alternative Covid-19 vaccines.
The government suspended administration of the first dose on April 26, immediately after the Indian government barred export of Covishield -- the AstraZeneca vaccine produced by the Serum Institute of India.
The Directorate General of Health Services (DGHS) yesterday said the stock of the Covid-19 vaccine is running out as there are only 14 lakh jabs in stock with no sign of fresh shipment from India.
There will be a vaccine crisis if a fresh consignment does not arrive in the country before the existing stock is exhausted, DGHS spokesperson Dr Robed Amin said.